Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

Mark A. Boyd*, Janaki Amin, Patrick W.G. Mallon, Nagalingeswaran Kumarasamy, Johan Lombaard, Robin Wood, Ploenchan Chetchotisakd, Praphan Phanuphak, Lerato Mohapi, Iskandar Azwa, Waldo H. Belloso, Jean Michel Molina, Jennifer Hoy, Cecilia L. Moore, Sean Emery, David A. Cooper, SECOND-LINE Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study'. Together they form a unique fingerprint.

Medicine & Life Sciences